Background: In 2018, GOLD addressed the issues of genotypes associated with risk factors for COPD. The genome-wide association study (GWAS) demonstrated an association between COPD and several genetic variants of single nucleotide polymorphisms (SNPs) of the FAM13A gene with the risk of COPD. Objective: To study the single nucleotide polymorphisms rs2869967 and rs17014601 of the FAM13A gene in chronic obstructive pulmonary disease. Subjects and research methods: 80 subjects diagnosed with COPD and 80 subjects determined not to have COPD according to GOLD 2020 criteria; the subjects were clinically examined, interviewed, and identified as possessing single nucleotide polymorphisms using the sanger sequencing method on whole blood samples. Results: The male/female ratio of the patient group and the control group was 79/1 and 39/1, respectively. The percentages of C and T alleles of rs2869967 in COPD patients were 50.6% and 49.4%, respectively. The percentages of C and T alleles of rs17014601 in COPD patients were 31.9% and 68.1%, respectively. At rs17014601, the ratio values of alleles T and C in the disease group and the control group were markedly different, making them statistically reliable (p = 0.031). The rate of CT genotype in the group of patients was considerably higher than that of the control group. The TT homozygous genotype had a lower risk of COPD compared with the other genotypes in the dominant model (ORTT/(CC + CT) = 0.441; CI95% = 0.233–0.833); this difference was statistically significant (p = 0.012). Conclusions: With rs17014601, it is characteristic that the frequency of the T allele appears more than the C allele, and the CT heterozygous phenotype accounts for the highest proportion in rs17014601 and rs2869967 recorded in COPD patients. There is an association between the genetic variant of the SNP FAM13A-rs17014601 and the risk of COPD.

Background: There have not been many studies evaluating the results of Diacerein treatment in patients with knee osteoarthritis (OA) and obesity, particularly comparing dosage levels of 50 and 100 mg/day. Methods: A randomized, single-blind, noncontrolled clinical trial was conducted at the Ho Chi Minh City Hospital for Rehabilitation, Vietnam, from January 2023 to January 2024. Patients with odd-numbered records received Diacerein 50 mg/day, while those with even-numbered records received 100 mg/day. Primary outcomes included symptom and functional improvements, assessed using visual analogue scale (VAS) and Western Ontario and McMaster University Osteoarthritis (WOMAC) scores at weeks 4 and 8. Results: A total of 256 patients (average age 58.3 ± 12.0 years; 59.4% female) were included, and 53.1% reported moderate pain, with average VAS and WOMAC scores of 64.7 ± 14.4 mm and 51.7 ± 11.4 points, respectively. Increased waist circumference, triglycerides (TG), and TG/high density of lipoprotein cholesterol ratio were identified as risk factors for severe knee OA, with respective odds ratio of 4.9 (1.6–14.7), 47 (12.5–176.1), and 22.5 (6.7–75.9). Diacerein significantly improved symptoms and joint function, with the 100-mg/day group showing faster and greater average reductions in VAS and WOMAC scores at weeks 4 and 8. The most notable reduction was 26.7 ± 11.3 for VAS and 20.7 ± 8.9 for WOMAC in week 4. Conclusion: Increased waist circumference, plasma TG, and TG/high density of lipoprotein cholesterol ratio raise the risk of severe knee OA. Diacerein treatment improves symptoms and joint function in patients with knee OA accompanied by obesity, with the 100-mg/day dose showing earlier and more effective improvement than the 50-mg/day dose.